title: Antitumoral effect of Ocoxin on acute myeloid leukemia.
abstract: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy whose incidence is growing in developed countries. In the relapse setting, very limited therapeutic options are available and in most cases only palliative care can be offered to patients. The effect of a composite formulation that contains several antioxidants, Ocoxin Oral solution (OOS), was tested in this condition. When analyzed in vitro, OOS exhibited anti-AML action that was both time and dose dependent. In vivo OOS induced a ralentization of tumor growth that was due to a decrease in cell proliferation. Such effect could, at least partially, be due to an increase in the cell cycle inhibitor p27, although other cell cycle proteins seemed to be altered. Besides, OOS induced an immunomodulatory effect through the induction of IL6. When tested in combination with other therapeutic agents normally used in the treatment of AML patients, OOS demonstrated a higher antiproliferative action, suggesting that it may be used in combination with those standard of care treatments to potentiate their antiproliferative action in the AML clinic.
authors.affiliation: Instituto de Biología Molecular y Celular del Cáncer CSIC-Universidad de Salamanca, Salamanca, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Díaz-Rodríguez
authors.affiliation: Instituto de Biología Molecular y Celular del Cáncer CSIC-Universidad de Salamanca, Salamanca, Spain.
authors.forename: Susana
authors.initials: S
authors.lastname: Hernández-García
authors.affiliation: Catalysis, S.L., Madrid, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Sanz
authors.affiliation: Instituto de Biología Molecular y Celular del Cáncer CSIC-Universidad de Salamanca, Salamanca, Spain.
authors.forename: Atanasio
authors.initials: A
authors.lastname: Pandiella
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001205:Ascorbic Acid / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D005492:Folic Acid; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D010205:Pantothenic Acid; D010936:Plant Extracts / Q000494:pharmacology*; D011897:Random Allocation; D014805:Vitamin B 12 / Q000494:pharmacology*; D025101:Vitamin B 6 / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays; D019287:Zinc Sulfate
chemical_list: D000975:Antioxidants; C000611825:Ocoxin; D010936:Plant Extracts; D010205:Pantothenic Acid; D019287:Zinc Sulfate; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12; D001205:Ascorbic Acid
keywords: acute myeloid leukemia; antioxidants; cell cycle; p27